Published in Curr Med Chem on January 01, 2013
Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int (2014) 0.95
Efficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature Data. Drugs R D (2016) 0.79
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum (2000) 11.84
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Introduction and General Overview of Cyclodextrin Chemistry. Chem Rev (1998) 4.91
The effect of education, assessment and a standardised prescription on postoperative pain management. The value of clinical audit in the establishment of acute pain services. Anaesthesia (1998) 4.72
Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med (2002) 4.21
Frequency of analgesic use and risk of hypertension among men. Arch Intern Med (2007) 3.29
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation (2007) 3.27
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med (2000) 3.26
Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med (1991) 3.05
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J (2004) 2.75
Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol (2009) 2.73
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med (2011) 2.64
Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis (2004) 2.64
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology (2000) 2.43
Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf (2006) 2.38
Supramolecular chemistry: receptors, catalysts, and carriers. Science (1985) 2.38
Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation (2006) 2.26
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain (2001) 2.20
A model to evaluate mild analgesics in oral surgery outpatients. Clin Pharmacol Ther (1976) 2.19
Cyclodextrins. Toxicol Pathol (2008) 2.11
Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) 2.01
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J (2007) 2.00
The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med (1992) 1.98
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J (2006) 1.96
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol (2007) 1.94
Cyclodextrins: their future in drug formulation and delivery. Pharm Res (1997) 1.85
Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci (1997) 1.80
Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med (1994) 1.79
The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ (1992) 1.72
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol (2000) 1.70
A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med (1993) 1.68
Effect of postoperative experiences on willingness to pay to avoid postoperative pain, nausea, and vomiting. Anesthesiology (2006) 1.67
Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci (1996) 1.67
Piroxicam--a literature review of new results from laboratory and clinical studies. Eur J Rheumatol Inflamm (1983) 1.58
Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf (2004) 1.56
Cyclodextrins in drug delivery. Expert Opin Drug Deliv (2005) 1.55
Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol (2002) 1.49
Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology (2005) 1.46
Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology (Oxford) (2008) 1.45
Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol (2008) 1.45
The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol (2002) 1.44
Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ (2003) 1.42
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther (2008) 1.38
The design of molecular hosts, guests, and their complexes. Science (1988) 1.36
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol (2006) 1.34
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol (2000) 1.31
Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol (1984) 1.29
Swallowing disorders in the elderly. Laryngoscope (2002) 1.28
Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol (2001) 1.24
Medicinal applications of cyclodextrins. Med Res Rev (1994) 1.23
Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev (2010) 1.21
Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am (2010) 1.19
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet (1994) 1.15
Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception (2009) 1.12
Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med (2006) 1.11
Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl (2003) 1.10
Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol (1999) 1.07
Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med (1999) 1.04
Dysmenorrhea in adolescents: diagnosis and treatment. Paediatr Drugs (2008) 1.04
Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis (2004) 1.03
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis (2010) 1.02
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord (2006) 1.01
Gastrointestinal transit and drug absorption. Biol Pharm Bull (2002) 1.01
Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method. Dig Dis Sci (1990) 1.01
Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion (2006) 1.01
Role of cyclooxygenase isoforms in gastric mucosal defence. J Physiol Paris (2001) 1.01
Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging (2007) 1.00
Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum (2008) 0.99
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res (2008) 0.99
Nonsteroidal anti-inflammatory drugs: a critical review on current concepts applied to reduce gastrointestinal toxicity. Curr Med Chem (2009) 0.98
Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord (2012) 0.98
Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) (2009) 0.97
Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs (2010) 0.96
Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin (2007) 0.95
Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther (2004) 0.94
Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: characterization and in vitro permeation study. Eur J Med Chem (2005) 0.94
Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet (2007) 0.94
Dysmenorrhea in adolescents. Ann N Y Acad Sci (2008) 0.93
Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther (2008) 0.92
Clinical pharmacokinetics of piroxicam. J Rheumatol (1986) 0.91
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? Inflammopharmacology (2010) 0.91
Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris (2001) 0.89
Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. Gastroenterol Clin North Am (2009) 0.88
Inclusion compounds of non-steroidal antiinflammatory and other slightly water soluble drugs with alpha- and beta-cyclodextrins in powdered form. Chem Pharm Bull (Tokyo) (1975) 0.88
Myths and facts in the use of anti-inflammatory drugs. Ann Med (2009) 0.88
Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol (2005) 0.86
Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol (2003) 0.86
Upper gastrointestinal complications among users of paracetamol. Basic Clin Pharmacol Toxicol (2006) 0.85
Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs (1984) 0.85
Application of supercritical carbon dioxide for the preparation of a piroxicam-beta-cyclodextrin inclusion compound. Pharm Res (1999) 0.85
Acetylsalicylic acid and gastrointestinal bleeding measurement of blood loss using a modified radioactive chromium method. Scand J Gastroenterol (1975) 0.85
Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands. Curr Med Res Opin (2009) 0.84
Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res (1998) 0.84
Influence of cyclodextrin complexation with NSAIDs on NSAID/cold stress-induced gastric ulceration in rats. Int J Med Sci (2010) 0.84